Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher tous les synonymes
Sélectionnez vos espèces d'intérêt
Human BRAF Protein expressed in HEK-293 Cells - ABIN2715104
Arnoux, Fina, Lambert, Balandraud, Martin, Ouafik, Kanaan, Roudier, Auger: Newly Identified BRAF Mutation in Rheumatoid Arthritis. dans Arthritis & rheumatology (Hoboken, N.J.) 2016
BRAF mutations more frequently affected individuals younger than 61 with phototype II. In contrast, NRAS (Montrer NRAS Protéines) mutations were more frequent in phototype III cases. Mutations of both genes were more frequent in cases with satellitosis in the first melanoma, and in cases with ulceration in the subsequent lesions.
Identification of KRAS/NRAS/BRAF mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer.
we did not observe GNAS (Montrer GNAS Protéines) or BRAF mutations in urachal adenocarcinomas
Study finds infrequent BRAF alterations but enriched FGFR (Montrer FGFR2 Protéines) alterations in adults as compared with that reported in pediatric pilocytic astrocytomas. In addition, coexistent BRAF and FGFR (Montrer FGFR2 Protéines) alterations and a significant association of FGFR (Montrer FGFR2 Protéines) alterations with age and tumor location were noted.
a low frequency of BRAF or KRAS mutation in Chinese patients with low-grade serous carcinoma of the ovary
genetic association studies in population in China: Data suggest that, in patients with unilateral papillary thyroid carcinoma, a mutation in BRAF (V600E) plus multi-focality are both independently and synergically associated with CLNM (central lymph node metastasis) in the population studied.
RHEB (Montrer RHEB Protéines) Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB (Montrer RHEB Protéines) and BRAF resulting in overactive RAF (Montrer RAF1 Protéines)/MEK (Montrer MAP2K1 Protéines)/ERK (Montrer EPHB2 Protéines) signaling. Taken together with the previously established function of RHEB (Montrer RHEB Protéines) to activate mTORC1 signaling, it appears that RHEB (Montrer RHEB Protéines) performs a dual function; one is to suppress the RAF (Montrer RAF1 Protéines)/MEK (Montrer MAP2K1 Protéines)/ERK (Montrer EPHB2 Protéines) signaling and the other is to activate mTORC1 signaling.
The MLH1 (Montrer MLH1 Protéines)-93 AA genotype is significantly associated with promoter hypermethylation and MLH1 (Montrer MLH1 Protéines) loss in the context of Sessile serrated adenoma of dysplasia. BRAF mutant microsatellite stable colorectal cancers with the AA genotype most likely arise in traditional serrated adenomas since the A allele does not predispose to methylation in this context.
Knowing the mutation status of KRAS, BRAF or PIK3CA (Montrer PIK3CA Protéines) in stage II colorectal cancer can significantly improve the accuracy of prognoses.
Mutated Liquid-based FNAs BRAF, N/HRAS (Montrer HRAS Protéines) and TERT (Montrer TERT Protéines) mutations were significantly associated with malignancy regardless of the cytological classification
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (Montrer TWIST2 Protéines) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (Montrer CDX2 Protéines)(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 (Montrer CDX2 Protéines) silencing to alter gene expression. Like human serrated lesions, CDX2 (Montrer CDX2 Protéines)(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (Montrer SLITRK1 Protéines) reduces copper levels and MAPK (Montrer MAPK1 Protéines) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (Montrer ROCK2 Protéines) form independent RAF1 (Montrer RAF1 Protéines) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (Montrer EGF Protéines)).
Braf(V600E) expression, coupled with simultaneous p53 (Montrer TP53 Protéines) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (Montrer RAF1 Protéines) operate independently to balance MAPK (Montrer MAPK1 Protéines) signaling: BRAF promotes ERK (Montrer EPHB2 Protéines) activation, while RAF1 (Montrer RAF1 Protéines) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (Montrer PAX3 Protéines).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein